Smoking Cessation - Evotec Reports Phase I Safety Data From Tyramine Interaction Study With EVT 302
Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today encouraging results of a Phase I safety study investigating the potential interaction of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B) in development for smoking cessation, with tyramine. The study was undertaken to determine potential safety advantages of EVT 302 versus non-selective MAO inhibitors and less selective MAO-B inhibitors already on the market.
More: continued here